SG&A Spending Patterns: GSK plc vs. Novavax, Inc.

In the ever-evolving pharmaceutical industry, understanding spending patterns is crucial. Over the past decade, GSK plc and Novavax, Inc. have demonstrated contrasting approaches to their Selling, General, and Administrative (SG&A) expenses. GSK, a global healthcare giant, consistently allocated substantial resources, with an average annual SG&A expense of approximately $9.8 billion. This reflects their expansive market reach and robust operational framework.

Conversely, Novavax, a smaller biotech firm, exhibited a more conservative spending pattern, averaging around $160 million annually. Notably, Novavax's SG&A expenses surged by over 2,300% from 2014 to 2023, highlighting their aggressive expansion and increased market activities, especially during the COVID-19 pandemic.

These spending trends underscore the strategic priorities of each company, with GSK focusing on maintaining its market dominance and Novavax investing in growth and innovation.